Trial data comparison: difference between revisions
Diff·revision 49 → 50·10:06, 14 Oct 2025
Difference between revision 49 and revision 50 of Trial data comparison. 3 lines changed; the page grew by 492 bytes.
| Revision 49 — 11:40, 7 Oct 2025 Chromatokid (talk) add see also 6,666 bytes ±0 | Revision 50 — 10:06, 14 Oct 2025 CiteBot (talk) bot: update parent category chain 7,158 bytes +492 | ||
|---|---|---|---|
| 63 | Three of the rows report hazard ratios for clinical events rather than changes in a measurement. These are the strongest evidence in the table and the least comparable to the rest of it: an event-driven trial reports a relative risk over years in a population selected for risk, and a hazard ratio cannot be placed alongside a percentage weight change in any meaningful ordering. | 63 | Three of the rows report hazard ratios for clinical events rather than changes in a measurement. These are the strongest evidence in the table and the least comparable to the rest of it: an event-driven trial reports a relative risk over years in a population selected for risk, and a hazard ratio cannot be placed alongside a percentage weight change in any meaningful ordering. |
| 64 | 64 | ||
| + | 65 | For those rows the useful companion figure is the [[Number needed to treat|number needed to treat]], which converts a relative effect into an absolute one over a stated horizon — and which is meaningless without that horizon.{{r|select}} | |
| + | 66 | ||
| 65 | == References == | 67 | == References == |
| 66 | {{reflist}} | 68 | {{reflist}} |
| ⋮ | ⋮ | ||
| 68 | <ref name="step1">Wilding JPH, Batterham RL, Calanna S, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." ''New England Journal of Medicine'' 384(11):989–1002 (2021). DOI:10.1056/NEJMoa2032183. PMID 33567185.</ref> | 70 | <ref name="step1">Wilding JPH, Batterham RL, Calanna S, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." ''New England Journal of Medicine'' 384(11):989–1002 (2021). DOI:10.1056/NEJMoa2032183. PMID 33567185.</ref> |
| 69 | <ref name="surpass2">Frías JP, Davies MJ, Rosenstock J, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." ''New England Journal of Medicine'' 385(6):503–515 (2021). DOI:10.1056/NEJMoa2107519. PMID 34170647.</ref> | 71 | <ref name="surpass2">Frías JP, Davies MJ, Rosenstock J, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." ''New England Journal of Medicine'' 385(6):503–515 (2021). DOI:10.1056/NEJMoa2107519. PMID 34170647.</ref> |
| + | 72 | <ref name="select">Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." ''New England Journal of Medicine'' 389(24):2221–2232 (2023). DOI:10.1056/NEJMoa2307563. PMID 37952131.</ref> | |
| 70 | <ref name="surmount1">Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." ''New England Journal of Medicine'' 387(3):205–216 (2022). DOI:10.1056/NEJMoa2206038. PMID 35658024.</ref> | 73 | <ref name="surmount1">Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." ''New England Journal of Medicine'' 387(3):205–216 (2022). DOI:10.1056/NEJMoa2206038. PMID 35658024.</ref> |
| 71 | 74 |